Anti-CD30 Therapies - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Anti-CD30 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD30 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anti-CD30 Therapies: Overview
CD30 (also known as TNFRSF8) is a 120-kD transmembrane protein of the tumor necrosis factor family. The protein is comprised of an extracellular domain, a transmembrane region and a cytoplasmic domain. The majority of antibodies against human CD30 recognize epitopes within the extracellular domain. CD30 signaling regulates peripheral T-cell responses, controlling T-cell survival, and downregulating cytolytic capacity. CD30 is expressed on activated T cells, NK cells, and B cells. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. Studies have also shown a role of CD30 as a T-cell costimulatory molecule involved in Th1, Th2, and Th17 immune responses. The restriction of CD30 expression on normal cells makes it an attractive candidate for targeted therapy. In studies, anti-CD30 antibodies alone display therapeutic efficacy, the newer agents markedly enhance antibody effectiveness through their conjugation with various cytotoxic agents. Hence, CD30 can serve both as a diagnostic marker for lymphocyte malignancies and as a target for therapy.
Report Highlights
This segment of the Anti-CD30 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD30 Therapies Emerging Drugs
Further product details are provided in the report……..
Anti-CD30 Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD30 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
Anti-CD30 Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD30 Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD30 Therapies drugs.
Anti-CD30 Therapies Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Anti-CD30 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD30 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anti-CD30 Therapies: Overview
CD30 (also known as TNFRSF8) is a 120-kD transmembrane protein of the tumor necrosis factor family. The protein is comprised of an extracellular domain, a transmembrane region and a cytoplasmic domain. The majority of antibodies against human CD30 recognize epitopes within the extracellular domain. CD30 signaling regulates peripheral T-cell responses, controlling T-cell survival, and downregulating cytolytic capacity. CD30 is expressed on activated T cells, NK cells, and B cells. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. Studies have also shown a role of CD30 as a T-cell costimulatory molecule involved in Th1, Th2, and Th17 immune responses. The restriction of CD30 expression on normal cells makes it an attractive candidate for targeted therapy. In studies, anti-CD30 antibodies alone display therapeutic efficacy, the newer agents markedly enhance antibody effectiveness through their conjugation with various cytotoxic agents. Hence, CD30 can serve both as a diagnostic marker for lymphocyte malignancies and as a target for therapy.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD30 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD30 Therapies.
This segment of the Anti-CD30 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD30 Therapies Emerging Drugs
- Brentuximab vedotin - Seagen/Takeda
- AFM13: Affimed
Further product details are provided in the report……..
Anti-CD30 Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD30 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anti-CD30 Therapies
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Anti-CD30 Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD30 Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD30 Therapies drugs.
Anti-CD30 Therapies Report Insights
- Anti-CD30 Therapies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anti-CD30 Therapies drugs?
- How many Anti-CD30 Therapies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD30 Therapies?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD30 Therapies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD30 Therapies and their status?
- What are the key designations that have been granted to the emerging drugs?
- Seagen
- Takeda Oncology
- Cellular Biomedicine Group
- Wuhan Bio Raid Biotechnology
- Affimed
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.
- Tessa Therapeutics
- Brentuximab vedotin
- CART 30
- Anti-CD30 chimeric antigen receptor T-cell therapy
- AFM13
- F0002-ADC
- TT 11
- SGN-CD30C
Introduction
Executive Summary
Anti-CD30 Therapies: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD30 Therapies – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD30 Therapies companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD30 Therapies Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Brentuximab vedotin: Seagen/Takeda Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AFM13: Affimed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Anti-CD30 chimeric antigen receptor T-cell therapy: Wuhan Bio Raid Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD30 Therapies Key Companies
Anti-CD30 Therapies Key Products
Anti-CD30 Therapies- Unmet Needs
Anti-CD30 Therapies- Market Drivers and Barriers
Anti-CD30 Therapies- Future Perspectives and Conclusion
Anti-CD30 Therapies Analyst Views
Anti-CD30 Therapies Key Companies
Appendix
Executive Summary
Anti-CD30 Therapies: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anti-CD30 Therapies – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anti-CD30 Therapies companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anti-CD30 Therapies Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Brentuximab vedotin: Seagen/Takeda Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AFM13: Affimed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Anti-CD30 chimeric antigen receptor T-cell therapy: Wuhan Bio Raid Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Anti-CD30 Therapies Key Companies
Anti-CD30 Therapies Key Products
Anti-CD30 Therapies- Unmet Needs
Anti-CD30 Therapies- Market Drivers and Barriers
Anti-CD30 Therapies- Future Perspectives and Conclusion
Anti-CD30 Therapies Analyst Views
Anti-CD30 Therapies Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anti-CD30 Therapies
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anti-CD30 Therapies
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anti-CD30 Therapies
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anti-CD30 Therapies
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products